The present invention relates to a composition and a kit for assessing the quality of stem cells, and a method for producing stem cells, and may provide a cell therapy product and a composition for preventing or treating immune-related disease.

Described in certain example embodiments herein are compositions and methods to determine fertility fitness in mammals.

A novel combinatorial and high-throughput platform that enables rapid screening of complex and heterogeneous copolymer brushes as enzyme immobilization supports named Combinatorial High-throughput Enzyme Support Screening (CHESS). Using a 384 well-plate format, we synthesized arrays of three-component polymer brushes in the microwells using photo-activated surface-initiated polymerization, and immobilized enzymes in situ. The utility of CHESS to identify optimal immobilization supports under thermally and chemically denaturing conditions was demonstrated using Bacillus subtilis Lipase A (LipA). The identification of supports with optimal compositions was validated by immobilizing LipA on polymer-brush modified biocatalyst particles. We further demonstrated that CHESS could be used to predict the optimal composition of polymer brushes a priori for the previously unexplored enzyme, alkaline phosphatase (AlkP). Our findings demonstrate that CHESS represents a predictable and reliable platform for dramatically accelerating the search of chemical compositions for immobilization supports and further facilitate the discovery of biocompatible and stabilizing materials.

This disclosure relates to antibodies and derivatives that bind the full-length isoform of aspartate beta-hydroxylase (ASPH) and uses thereof. The antibodies and derivatives are useful in compositions and methods for detecting and/or treating a malignant neoplasm in a subject and for predicting subsequent complications of untreated progression of the malignant neoplasm in the subject.

The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising a COX2 acetylating agent as an active ingredient and, more particularly, to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising, as an active ingredient, a COX2 acetylating agent which exhibits an effect of inhibiting the deposition of amyloid- in brain neurons, reducing excessive neuroinflammatory responses, and increasing the phagocytosis of amyloid- in microglial cells. The pharmaceutical composition for preventing or treating neurodegenerative diseases comprising the COX2 acetylating agent as an active ingredient has the effects of alleviating neuroinflammation by promoting COX2 acetylation in neurons and secreting specialized pro-resolving mediators (SPMs) and thus, can be very useful in the development of a preventive or therapeutic agent for neurodegenerative diseases.

The present invention relates to an antibody for detecting acetylation of COX2 protein, and uses thereof, and more specifically, to an antibody that specifically recognizes the acetylation of S565 residue of the COX2 protein; and uses thereof for diagnosing neurodegenerative diseases or inflammatory diseases. An antibody or a functional fragment thereof according to the present invention specifically binds to an acetylated residue of COX2 protein, and can thus be very effectively used for diagnosing neurodegenerative diseases, inflammatory diseases, and the like in which the degree of acetylation of S565 residue of the COX2 protein is reduced.